Fluticasone Furoate/GW642444 Inhalation Powder Long-Term Safety Study

PHASE3CompletedINTERVENTIONAL
Enrollment

503

Participants

Timeline

Start Date

October 19, 2009

Primary Completion Date

May 1, 2011

Study Completion Date

May 12, 2011

Conditions
Asthma
Interventions
DRUG

Fluticasone Furoate/GW642444

Combination inhaled corticosteroid and long-acting beta2-agonist

DRUG

Fluticasone propionate

Inhaled corticosteroid

Trial Locations (47)

10330

GSK Investigational Site, Bangkok

10365

GSK Investigational Site, Berlin

10367

GSK Investigational Site, Berlin

10400

GSK Investigational Site, Bangkok

10717

GSK Investigational Site, Berlin

13086

GSK Investigational Site, Berlin

13581

GSK Investigational Site, Berlin

14469

GSK Investigational Site, Potsdam

20814

GSK Investigational Site, Bethesda

23858

GSK Investigational Site, Reinfeld

27607

GSK Investigational Site, Raleigh

36203

GSK Investigational Site, Oxford

40002

GSK Investigational Site, Khon Kaen

45231

GSK Investigational Site, Cincinnati

49027

GSK Investigational Site, Dnipropetrovsk

49051

GSK Investigational Site, Dnipropetrovsk

50200

GSK Investigational Site, Chiang Mai

53228

GSK Investigational Site, Greenfield

63071

GSK Investigational Site, Offenbach

68161

GSK Investigational Site, Mannheim

73103

GSK Investigational Site, Oklahoma City

75230

GSK Investigational Site, Dallas

76712

GSK Investigational Site, Waco

78229

GSK Investigational Site, San Antonio

78750

GSK Investigational Site, Austin

79903

GSK Investigational Site, El Paso

83017

GSK Investigational Site, Donetsk

83099

GSK Investigational Site, Donetsk

86825

GSK Investigational Site, Bad Woerrishofen

90274

GSK Investigational Site, Rolling Hills Estates

92647

GSK Investigational Site, Huntington Beach

92691

GSK Investigational Site, Mission Viejo

95034

GSK Investigational Site, Simferopol

95207

GSK Investigational Site, Stockton

68123-4303

GSK Investigational Site, Bellevue

08558

GSK Investigational Site, Skillman

05403

GSK Investigational Site, South Burlington

01067

GSK Investigational Site, Dresden

04103

GSK Investigational Site, Leipzig

04357

GSK Investigational Site, Leipzig

01445

GSK Investigational Site, Radebeul

04626

GSK Investigational Site, Schmölln

02091

GSK Investigational Site, Kyiv

02660

GSK Investigational Site, Kyiv

03038

GSK Investigational Site, Kyiv

03680

GSK Investigational Site, Kyiv

04050

GSK Investigational Site, Kyiv

Sponsors

Lead Sponsor

All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY

NCT01018186 - Fluticasone Furoate/GW642444 Inhalation Powder Long-Term Safety Study | Biotech Hunter | Biotech Hunter